Skip to content
DataLookout
Menu

HARMONi-7NCT06767514

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 11 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 274 → 285 locations
    • Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 1 of 4 entries
  2. Minor Trial sites expanded: 270 → 274 locationsv10
  3. Minor Trial sites expanded: 202 → 270 locationsv9
  4. Minor Study sites: 120 to 202v8
  5. Minor Study sites: 94 to 120v7
Show 5 earlier versionsHide 5 earlier versions
  1. Minor Study sites: 74 to 94v6
  2. Minor Study sites: 45 to 74v5
  3. Minor Study sites: 23 to 45v4
  4. Minor Study sites: 3 to 23
    • Start date changed from estimate of Jan 2025 to Feb 27, 2025
    v3
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date: Dec 31, 2024 to Jan 2025
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall Survival (OS)
Timeframe: Up to approximately 36 months
Progression free survival (PFS)
Timeframe: Up to approximately 36 months

Secondary (4)

Objective response rate (ORR)
Disease control rate ( DCR)
Duration of response (DoR)
Adverse Events (AE): incidence and severity of adverse events (AEs) and clinically significant abnormal laboratory test results

Arms and interventions

Arm A - IvonescimabExperimental

Subject will receive ivonescimab as an IV injection

Arm B - PembrolizumabActive comparator

Subject will receive pembrolizumab as an IV injection

Biologicals: Ivonescimab Injection, Pembrolizumab Injection

Sites

285 sites in 17 countries

United States 97, China 34, Spain 25, Japan 20, Turkey (Türkiye) 17, Mexico 15, France 14, Romania 11, Italy 10, Germany 9, Greece 6, Portugal 6, Hungary 5, Poland 5, Canada 4, Serbia 4, Belgium 3